These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The type 1 insulin-like growth factor receptor signalling system and targeted tyrosine kinase inhibition in cancer. Haisa M J Int Med Res; 2013 Apr; 41(2):253-64. PubMed ID: 23569026 [TBL] [Abstract][Full Text] [Related]
4. Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. Vincent EE; Elder DJ; Curwen J; Kilgour E; Hers I; Tavaré JM PLoS One; 2013; 8(6):e66963. PubMed ID: 23826179 [TBL] [Abstract][Full Text] [Related]
5. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment. You L; Liu C; Tang H; Liao Y; Fu S Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362 [TBL] [Abstract][Full Text] [Related]
6. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy. Werner H; Sarfstein R; Bruchim I Expert Opin Investig Drugs; 2019 Dec; 28(12):1101-1112. PubMed ID: 31731883 [No Abstract] [Full Text] [Related]
7. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. Beltran PJ; Chung YA; Moody G; Mitchell P; Cajulis E; Vonderfecht S; Kendall R; Radinsky R; Calzone FJ J Pharmacol Exp Ther; 2011 Jun; 337(3):644-54. PubMed ID: 21385891 [TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor receptor inhibitors: baby or the bathwater? Yee D J Natl Cancer Inst; 2012 Jul; 104(13):975-81. PubMed ID: 22761272 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Tao Y; Pinzi V; Bourhis J; Deutsch E Nat Clin Pract Oncol; 2007 Oct; 4(10):591-602. PubMed ID: 17898809 [TBL] [Abstract][Full Text] [Related]
18. Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: a review. Ozkan EE Mol Cell Endocrinol; 2011 Sep; 344(1-2):1-24. PubMed ID: 21782884 [TBL] [Abstract][Full Text] [Related]
19. IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice. Moody G; Beltran PJ; Mitchell P; Cajulis E; Chung YA; Hwang D; Kendall R; Radinsky R; Cohen P; Calzone FJ J Endocrinol; 2014 Apr; 221(1):145-55. PubMed ID: 24492468 [TBL] [Abstract][Full Text] [Related]
20. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Scagliotti GV; Novello S Cancer Treat Rev; 2012 Jun; 38(4):292-302. PubMed ID: 21907495 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]